Toll-like Receptors and Artificial Intelligence in Fertility Management: Clinical Research Snapshot in United States of America and Asia-Pacific India Genetic Landscapes

Editorial Letter

Toll-like Receptors and Artificial Intelligence in Fertility Management: Clinical Research Snapshot in United States of America and Asia-Pacific India Genetic Landscapes

  • Saumya Pandey

Head, Department of Clinical Research, Indira IVF Hospital, Udaipur-Lucknow, India (formerly).

*Corresponding Author: Saumya Pandey,Head, Department of Clinical Research, Indira IVF Hospital, Udaipur-Lucknow, India (formerly).

Citation: Pandey S. (2024). Toll-like Receptors and Artificial Intelligence in Fertility Management: Clinical Research Snapshot in United States of America and Asia-Pacific India Genetic Landscapes, Clinical Research and Reports, BioRes Scientia Publishers. 2(1):1-3. DOI: 10.59657/2995-6064.brs.23.003

Copyright: © 2024 Saumya Pandey, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: August 07, 2023 | Accepted: August 21, 2023 | Published: January 03, 2024

Abstract

Dissecting the intricate “maternal-fetal immune cross-talks” in the complex etiopathogenesis of reproductive endocrinology disorders primarily Mycobacterium tuberculi mediated female infertility and Chlamydia trachomatis mediated male infertility in genetically disparate susceptible “at-risk” cohorts of heterogeneous population-pools by amalgamating precision-based therapeutic targeting of Ceramide-Wnt/Frizzled-Toll like receptors-autophagy biochemical/metabolic signaling cascades with Artificial Intelligence (AI) offers fascinating healthcare management avenues in timeline-driven pragmatic, evidence-based predictive biomarker development in the Covid-19/Omicron vaccination era.


Keywords: fertility; etiopathogenesis; immune; healthcare; biomarker; reproductive

Introduction

Dissecting the intricate “maternal-fetal immune cross-talks” in the complex etiopathogenesis of reproductive endocrinology disorders primarily Mycobacterium tuberculi mediated female infertility and Chlamydia trachomatis mediated male infertility in genetically disparate susceptible “at-risk” cohorts of heterogeneous population-pools by amalgamating precision-based therapeutic targeting of Ceramide-Wnt/Frizzled-Toll like receptors-autophagy biochemical/metabolic signaling cascades with Artificial Intelligence (AI) offers fascinating healthcare management avenues in timeline-driven pragmatic, evidence-based predictive biomarker development in the Covid-19/Omicron vaccination era [1-4]. Interestingly, CRISPR-Cas genetic bio-engineering is emerging as an enigmatic modulator of complex human diseases including urological and sexually transmitted diseases by using genome editing and detecting specific DNA/RNA sequences to control gene expression warranting future multicentric dynamic collaborations for immuno-inflammatory disease(s)-management in the global Covid-19/Omicron pandemic and Covid-19 vaccination era [5]. In my expert opinion, the disproportionate share of overwhelming psychosexual distress and neuro-behavioral deficits warrants a robust, evidence-based, pragmatic “AI-fertility immunotherapeutic algorithmic precision medicine model” for design of pharmacological scaffolds, novel drugs and clinically validated predictive biomarkers for effective management of STDs and clinical infertility amongst genetically susceptible at-risk cohorts of asymptomatic vs borderline vs symptomatic subsets of varying life-styles, including tobacco-users (smokers/chewers).

During my recent meaningful collaborative discussions with urology-fertility-oncology experts of New York, USA and Lucknow/New Delhi, India, I gained critical insights in the AI algorithms and sophisticated predictive nomograms for precision-based image-quality and time-lapse real-time embryo-morpho kinetics immune-diagnostic assessment(s) of the hypoxic, vascular insufficient and inflammatory maternal-fetal microenvironment/ heterogeneous tissue core in the developing fetus and embryonic tissue;  AI-fertility management in clinical infertility patients of American and Asian-Indian genetic profiles/ethnicities would eventually lead to evidence-based reproductive outcomes for high-quality treatment and patient-satisfaction on a global platform.

Abnormal endocytosis and cleavage-patterns in embryonic induction, embryogenesis, viral/bacterial infection(s) in female/male infertility may be attributed to alterations in the Toll-like Receptors/Wnt-Frizzled receptors/ Autophagy biochemical/metabolic immune-intersections [6]. Intriguingly, the emergence of AI in fertility-medicine clinical research undoubtedly offers myriad immune-pharmacological opportunities to demystify the intricacies involved in tobacco-mediated infertility for achieving the ‘’quadruple objective(s)’’: improving patient experience (enhancing productivity along with efficacy in healthcare delivery); improving population health; transcribing prescriptions, treating patients remotely/virtually, and diminishing per person healthcare expenses [7-10]; and increasing the working conditions of healthcare professionals worldwide.

AI algorithms are extensively used in healthcare, including accuracy-based diagnostics, development of treatment protocols, medication research and therapeutics, customized “tailor-made” treatment regimens, clinical risk-assessment, healthcare data-privacy/security, image quality-analysis, digital health, AI-assisted robotic surgery, and health monitoring/surveillance. Overall, the future years hold tremendous potential for designing a well-defined pragmatic and ethical “AI-TLR-Autophagy-Wnt/CRISPR-Cas Fertility-Immune Genetic Blue-Print” healthcare roadmap for diminishing the overwhelming public health challenge of tobacco-mediated infertility amongst diverse population-pools of genetically mixed ethnicities worldwide.

Acknowledgements

Dr. Pandey acknowledges her collaborative clinical and biomedical research 1-1 discussions related to Autophagy-Wnt-TLRs and immune-inflammatory diseases, including AI-Fertility strategic management, at New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and UTMB, Galveston, TX, USA and UTMDACC, Houston, TX, USA.

Financial Disclosures

SP has no relevant financial disclosures and conflicts of interest to declare.

References